SI2398473T1 - 5-(2-((6-(2, 2-difluoro-2-feniletoksi)heksil)amino)-1-hidroksietil)-8-hidroksikvino- lin-2-(1H)-on za zdravljenje pljučne funkcije - Google Patents

5-(2-((6-(2, 2-difluoro-2-feniletoksi)heksil)amino)-1-hidroksietil)-8-hidroksikvino- lin-2-(1H)-on za zdravljenje pljučne funkcije

Info

Publication number
SI2398473T1
SI2398473T1 SI201030360T SI201030360T SI2398473T1 SI 2398473 T1 SI2398473 T1 SI 2398473T1 SI 201030360 T SI201030360 T SI 201030360T SI 201030360 T SI201030360 T SI 201030360T SI 2398473 T1 SI2398473 T1 SI 2398473T1
Authority
SI
Slovenia
Prior art keywords
hexylcaminoc
hydroxyquinolin
phenylethoxy
difluoro
hydroxyethyl
Prior art date
Application number
SI201030360T
Other languages
English (en)
Inventor
Thorsten Ruf
Montejo Eric Massana
Original Assignee
Almirall S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall S.A. filed Critical Almirall S.A.
Publication of SI2398473T1 publication Critical patent/SI2398473T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
SI201030360T 2009-02-18 2010-02-18 5-(2-((6-(2, 2-difluoro-2-feniletoksi)heksil)amino)-1-hidroksietil)-8-hidroksikvino- lin-2-(1H)-on za zdravljenje pljučne funkcije SI2398473T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382020A EP2221055A1 (en) 2009-02-18 2009-02-18 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
EP10711830.9A EP2398473B1 (en) 2009-02-18 2010-02-18 5-(2-{[6-(2, 2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2-(1H)-one for the treatment of lung function
PCT/EP2010/001026 WO2010094483A1 (en) 2009-02-18 2010-02-18 5- (2-{ [6- (2, 2-difluoro-2-phenylethoxy) hexyl] amino} -1-hydroxyethyl) -8-hydroxyquinolin-2 (ih)-one for the treatment of lung function

Publications (1)

Publication Number Publication Date
SI2398473T1 true SI2398473T1 (sl) 2013-11-29

Family

ID=40833525

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201030360T SI2398473T1 (sl) 2009-02-18 2010-02-18 5-(2-((6-(2, 2-difluoro-2-feniletoksi)heksil)amino)-1-hidroksietil)-8-hidroksikvino- lin-2-(1H)-on za zdravljenje pljučne funkcije

Country Status (33)

Country Link
US (2) US20120029014A1 (sl)
EP (2) EP2221055A1 (sl)
JP (1) JP2012518019A (sl)
KR (1) KR20110123742A (sl)
CN (2) CN102325530A (sl)
AR (1) AR075432A1 (sl)
AU (1) AU2010214854A1 (sl)
CA (1) CA2749059C (sl)
CL (1) CL2011002001A1 (sl)
CO (1) CO6361939A2 (sl)
CY (1) CY1114484T1 (sl)
DK (1) DK2398473T3 (sl)
EA (1) EA022442B1 (sl)
EC (1) ECSP11011336A (sl)
ES (1) ES2430596T3 (sl)
HK (1) HK1159990A1 (sl)
HR (1) HRP20130917T1 (sl)
IL (1) IL213979A0 (sl)
ME (1) ME01757B (sl)
MX (1) MX2011008577A (sl)
MY (1) MY155657A (sl)
NZ (1) NZ593727A (sl)
PE (1) PE20120419A1 (sl)
PL (1) PL2398473T3 (sl)
PT (1) PT2398473E (sl)
RS (1) RS52951B (sl)
SG (2) SG2014012827A (sl)
SI (1) SI2398473T1 (sl)
TW (2) TW201442711A (sl)
UA (1) UA103370C2 (sl)
UY (1) UY32414A (sl)
WO (1) WO2010094483A1 (sl)
ZA (1) ZA201104654B (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2668941A1 (en) * 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688V0 (it) 1979-02-05 1979-02-05 Chiesi Paolo Parma Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore.
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
ATE164525T1 (de) 1990-09-26 1998-04-15 Pharmachemie Bv Inhalator mit einem reservoir für mehrere dosierte inhalationsmittel, mit transportvorrichtung und mit wirbelkammer
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
WO1994014492A2 (en) 1992-12-18 1994-07-07 Schering Corporation Inhaler for powdered medications
EP0820323B1 (en) 1995-04-14 2003-09-24 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
SI9620081B (en) 1995-06-21 2001-06-30 Asta Medica Ag Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
FR2903168B1 (fr) * 2006-06-30 2008-08-22 Fayard Eliane Bruleur pour realiser la combustion de substances reputees difficilement combustibles
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico

Also Published As

Publication number Publication date
EP2398473B1 (en) 2013-07-24
AU2010214854A1 (en) 2011-07-21
KR20110123742A (ko) 2011-11-15
UA103370C2 (uk) 2013-10-10
PE20120419A1 (es) 2012-05-09
EA022442B1 (ru) 2016-01-29
EP2398473A1 (en) 2011-12-28
WO2010094483A1 (en) 2010-08-26
TW201031408A (en) 2010-09-01
UY32414A (es) 2010-07-30
US20120029014A1 (en) 2012-02-02
AR075432A1 (es) 2011-03-30
CY1114484T1 (el) 2016-10-05
RS52951B (en) 2014-02-28
NZ593727A (en) 2013-07-26
ES2430596T3 (es) 2013-11-21
MX2011008577A (es) 2011-09-06
JP2012518019A (ja) 2012-08-09
CL2011002001A1 (es) 2011-11-11
MY155657A (en) 2015-11-13
SG173091A1 (en) 2011-08-29
CA2749059C (en) 2017-08-01
CN105326838A (zh) 2016-02-17
HK1159990A1 (en) 2012-08-10
HRP20130917T1 (hr) 2013-11-08
ME01757B (me) 2014-09-20
PL2398473T3 (pl) 2013-12-31
ECSP11011336A (es) 2011-10-31
IL213979A0 (en) 2011-08-31
ZA201104654B (en) 2012-02-29
EP2221055A1 (en) 2010-08-25
PT2398473E (pt) 2013-09-30
US20140343097A1 (en) 2014-11-20
EA201101210A1 (ru) 2012-03-30
CO6361939A2 (es) 2012-01-20
SG2014012827A (en) 2014-04-28
CN102325530A (zh) 2012-01-18
DK2398473T3 (da) 2013-10-21
CA2749059A1 (en) 2010-08-26
TW201442711A (zh) 2014-11-16

Similar Documents

Publication Publication Date Title
HK1187606A1 (zh) 取代的 -稠合含氮雜環化合物及其用途
AP2010005508A0 (en) Triazole derivatives useful for the treatment of diseases.
HK1179617A1 (en) 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro- [1,4]oxazepin-5-ylamine compounds 2567--[14]-3- 2367--[14]-5-
IL219133A0 (en) Antimicrobial compounds and methods of making and using the same
IL219135A0 (en) Antimicrobial compounds and methods of making and using the same
IL219325A0 (en) Gadd45beta targeting compounds, compositons comprising the same and uses thereof
SI2398473T1 (sl) 5-(2-((6-(2, 2-difluoro-2-feniletoksi)heksil)amino)-1-hidroksietil)-8-hidroksikvino- lin-2-(1H)-on za zdravljenje pljučne funkcije
HK1150555A1 (zh) 用於治療動脈硬化的 -嘧啶二元胺的應用
IL230635A (en) An outgrowth of 4,3,2,1-tetrahydroquinoline used to treat diabetes
EP2287155A4 (en) ACYLTHIOURE COMPOUND OR SALT THEREOF, AND USE OF THE COMPOUND OR SALT
IL257837A (en) Antimicrobial compounds and methods for their preparation and use
AP2013006987A0 (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
EP2509423A4 (en) PROCESS FOR THE PREPARATION OF DEFERASIROX AND DEFERASIROX POLYMORPHO
IL207520A (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
EP2296654A4 (en) 8-HYDROXYQUINOLINE DERIVATIVES FOR THE TREATMENT OF MALIGNANT HEMOPATHIES
EP2459573A4 (en) SUBSTITUTED 1,2-AZABORIN HETEROCYCLES
IL210290A0 (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
SI2406227T1 (sl) Postopek za pripravo 5-(2-((6-(2,2-difluoro-2-feniletoksi)heksil)amino) -1-hidroksikinolin-2(1H)-ona
SG10201406635QA (en) Antimicrobial compounds and methods of making and using the same
IL196602A0 (en) Processes for the preparation of montelukast
PL2896614T3 (pl) Sposoby i związki do wytwarzania normorfinanów
ZA201100468B (en) The treatment of helminthic infections
EP2328577A4 (en) TREATMENT OF LOSS OF HEARING
GB0809319D0 (en) The treatment of puritus
GB0719613D0 (en) The treatment of pruritis